HomeCompareOPHLY vs GBDC

OPHLY vs GBDC: Dividend Comparison 2026

OPHLY yields 3.41% · GBDC yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OPHLY wins by $761.80M in total portfolio value· pulled ahead in Year 7
10 years
OPHLY
OPHLY
● Live price
3.41%
Share price
$5.29
Annual div
$0.18
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$782.58M
Annual income
$740,792,960.47
Full OPHLY calculator →
GBDC
GBDC
● Live price
11.85%
Share price
$12.66
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.78M
Annual income
$16,389,263.41
Full GBDC calculator →

Portfolio growth — OPHLY vs GBDC

📍 OPHLY pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOPHLYGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OPHLY + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OPHLY pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OPHLY
Annual income on $10K today (after 15% tax)
$289.50/yr
After 10yr DRIP, annual income (after tax)
$629,674,016.40/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.11/yr
After 10yr DRIP, annual income (after tax)
$13,930,873.90/yr
At 15% tax rate, OPHLY beats the other by $615,743,142.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OPHLY + GBDC for your $10,000?

OPHLY: 50%GBDC: 50%
100% GBDC50/50100% OPHLY
Portfolio after 10yr
$401.68M
Annual income
$378,591,111.94/yr
Blended yield
94.25%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

OPHLY
Analyst Ratings
2
Sell
Consensus: Sell
Altman Z
5.0
Piotroski
8/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.6% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OPHLY buys
0
GBDC buys
0
No recent congressional trades found for OPHLY or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOPHLYGBDC
Forward yield3.41%11.85%
Annual dividend / share$0.18$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%51.1%
Portfolio after 10y$782.58M$20.78M
Annual income after 10y$740,792,960.47$16,389,263.41
Total dividends collected$779.53M$20.36M
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusSellBuy

Year-by-year: OPHLY vs GBDC ($10,000, DRIP)

YearOPHLY PortfolioOPHLY Income/yrGBDC PortfolioGBDC Income/yrGap
1$11,381$681.17$12,490$1,790.28$1.1KGBDC
2$13,627$1,449.07$16,522$3,157.73$2.9KGBDC
3$17,824$3,243.01$23,578$5,898.68$5.8KGBDC
4$27,000$7,928.61$37,115$11,886.75$10.1KGBDC
5$51,340$22,449.56$66,136$26,423.57$14.8KGBDC
6$134,722$79,788.74$137,257$66,491.44$2.5KGBDC
7← crossover$535,510$391,357.72$341,734$194,868.54+$193.8KOPHLY
8$3,480,692$2,907,695.93$1,050,788$685,133.02+$2.43MOPHLY
9$39,050,210$35,325,869.63$4,099,314$2,974,971.01+$34.95MOPHLY
10$782,576,685$740,792,960.47$20,775,530$16,389,263.41+$761.80MOPHLY

OPHLY vs GBDC: Complete Analysis 2026

OPHLYStock

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors. The company also provides GLACTIV and FORXIGA tablets for type 2 diabetes; FORXIGA tablets for the treatment of diabetes; ONOACT injections for tachyarrhythmia; OPALMON tablets to treat peripheral circulatory disorder; CORALAN for treatment of chronic heart failure; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONGENTYS tablets for the treatment of Parkinson's disease; PARSABIV, an intravenous injection for dialysis patients; STAYBLA tablets for overactive bladder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as RECALBON tablets for osteoporosis. In addition, it is developing products for esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, virus positive/negative solid carcinoma, gastric, esophageal, urothelial, hepatocellular, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative, autoimmune, narcolepsy, and thrombosis. The company was founded in 1717 and is headquartered in Osaka, Japan.

Full OPHLY Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this OPHLY vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OPHLY vs SCHDOPHLY vs JEPIOPHLY vs OOPHLY vs KOOPHLY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.